Scarica l'app Stockscreener
34.34
5.22%
-1.89
Dopo l'orario di chiusura:
34.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.23
Aprire:
$36.05
Volume 24 ore:
1.43M
Relative Volume:
0.96
Capitalizzazione di mercato:
$3.31B
Reddito:
$610.16M
Utile/perdita netta:
$-532.93M
Rapporto P/E:
-6.2112
EPS:
-5.5287
Flusso di cassa netto:
$-442.30M
1 W Prestazione:
-5.40%
1M Prestazione:
+3.81%
6M Prestazione:
-7.46%
1 anno Prestazione:
-24.36%
Intervallo 1D:
$34.19
$36.54
Intervallo di 1 settimana:
$34.19
$36.81
Portata 52W:
$25.81
$46.50
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
34.34 | 3.50B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx Pharmaceutical (RARE): Reassessing Valuation After Recent Share Price Rebound - Yahoo Finance
Frazier Life Sciences Management L.P. Acquires 325,000 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 3,081 Shares - MarketBeat
Ultragenyx (RARE) CFO Horn sells $112k in stock By Investing.com - Investing.com Canada
Ultragenyx (RARE) CFO Horn sells $112k in stock - Investing.com
Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
Is Ultragenyx Pharmaceutical Inc. (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Bank of Nova Scotia Purchases Shares of 241,985 Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Norges Bank Invests $35.77 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Holdings Boosted by Hsbc Holdings PLC - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock near bottom after declineJuly 2025 Recap & Safe Investment Capital Preservation Plans - Newser
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Sands Capital Management LLC - MarketBeat
Schroder Investment Management Group Acquires 71,888 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock attract long term capital inflowsLong Setup & Expert Verified Movement Alerts - Newser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight - Yahoo Finance Singapore
RARE: Phase 3 data in rare diseases and gene therapy filings are set to drive growth this year - TradingView
Skandinaviska Enskilda Banken AB publ Has $2.46 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Capital Fund Management S.A. Buys 43,903 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 03 - marketscreener.com
Loomis Sayles & Co. L P Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly resultsJuly 2025 Breakouts & Daily Volume Surge Signals - Newser
Legal & General Group Plc Purchases 54,837 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Will Ultragenyx Pharmaceutical Inc. (UP0) stock hit Wall Street targets2025 Valuation Update & Precise Buy Zone Tips - Newser
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx (RARE): Assessing Valuation as Revenue Growth and Clinical Progress Fuel Renewed Investor Interest - Yahoo Finance
Ultragenyx Shares Rally After FDA Updates Are They Priced Right for 2025? - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook - Sahm
Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook - MSN
Ultragenyx to Participate in Investor Conferences in December - Sahm
Rhenman & Partners Asset Management AB Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bear Alert: Will Ultragenyx Pharmaceutical Inc. stock see PE expansion2025 Earnings Surprises & Low Risk Entry Point Tips - BỘ NỘI VỤ
Is Ultragenyx Pharmaceutical Inc. stock positioned well for digital economyTake Profit & Accurate Entry/Exit Alerts - moha.gov.vn
Why Ultragenyx Pharmaceutical Inc. stock is favored by top institutionsNew Guidance & Daily Chart Pattern Signal Reports - moha.gov.vn
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $3.28 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Geode Capital Management LLC - MarketBeat
Barclays Maintains Ultragenyx Pharmaceutical (RARE) Overweight Recommendation - Nasdaq
Ultragenyx (NASDAQ: RARE) to join Citi, Evercore healthcare investor conferences - Stock Titan
RARE: Barclays Lowers Price Target Amid Maintaining Overweight R - GuruFocus
Connor Clark & Lunn Investment Management Ltd. Lowers Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharma stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Australia
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):